Neurofilament: The Journey of a General Marker of Axonal Damage to a Biomarker with Clinical Utility in Multiple Sclerosis & Future Utility in Multiple Indications

• Overview of evidence generation for neurofilament light chain over the last 10 years
• Importance of robust diagnostic testing systems with established performance characteristics for neurofilament testing in clinical trials
• Drug-diagnostic co-development in MS and neurodegenerative disorders

Speakers:

Nancy Krunic, Ph.D

Vice President & Precision Medicine Head, Diagnostic Sciences & Partnerships

Novartis